The Alzheimer Society Research Portal connects researchers with Canadians looking to participate in research studies. On this website, find active studies that you can participate in to help advance research on dementia.
This study aims to identify the gaps in the community-based supports and services to meet the needs of people living with dementia and their care partners. We hope that the findings will help inform the development and improvement of programs and services.
Exposure to nature—even just a few minutes at a time—supports improved attention, mood, self-regulation, and social connection.
“Green health initiatives” are outdoor or nature-based activities designed to have a potential positive impact on health. Some of these initiatives are specifically designed to include people living with dementia. These can include walking groups, golfing, farm gardening programs, and seasonal social activities located in parks or natural spaces. We are currently conducting an international literature review to find out more about when and how green health initiatives operate to generate benefits for people living with dementia. As part of this initiative, we are planning a series of three consultation events to learn more about the interests of people living with dementia. For each consultation, participants will receive a $20 Tim Horton's gift card in thanks for their time.
You are eligible if you are currently living with dementia.
This study evaluates an at-home, digital cognitive screening tool for older adults experiencing memory changes across the dementia continuum. Participants will complete a brief series of engaging, online brain games and surveys to determine the tool's accuracy compared to traditional clinical assessments. The goal of this study is to provide accessible, patient-friendly monitoring of brain health that reduces the need for clinic travel and lowers barriers to early detection of dementia.
You are eligible to participate if you:
Are 50 years of age or older
Either have healthy cognition or are experiencing noticeable memory or thinking changes (Subjective Cognitive Decline), or have a clinical diagnosis of Mild Cognitive Impairment (MCI) or dementia.
Have access to a computer, laptop, or tablet with a reliable internet connection.
Are able to provide informed consent, or have a legally authorized Substitute Decision Maker (SDM) who can provide consent on your behalf.
Have adequate vision and motor skills to view a screen and tap or click to respond to prompts (such as a choice reaction time task), using glasses or standard aids if necessary.
Are able to read and communicate in English.
Do not have comorbid psychiatric conditions that interfere with cognitive function Do not have a history of brain injury or neurodevelopmental disorders
This study will explore how online group singing can contribute to participants' sense of wellbeing, meaning, social connection, and learning. Participants are people living with memory concerns or dementia and their care partners, and must still live at home (i.e. not in long-term care). This mixed methods study will measure participants' (voluntary) responses to brief questions about their feelings before and after each rehearsal through visual analogue scales (quantitative). Participant engagement will be observed using the Group Observational Method of Engagement during rehearsals. Participants' (voluntary) verbatim narratives will be captured through interviews (qualitative) and analyzed using thematic analysis. Findings will form the basis of the choir facilitator's doctoral dissertation and may be included in academic journals or community workshops so that programming can be developed and improved for people living with dementia and their care partners.
You are eligible to participate if you:
- have memory concerns (whether or not diagnosed dementia) and still live at home (i.e. not in long-term care)
- are a care partner of someone with memory concerns (whether or not diagnosed dementia)
- are able to participate in the choir together in a pair
- have internet access
- have an interest in singing or music
This study looks at how an at-home nature-based virtual reality (VR) program may help people living with Alzheimer’s Disease manage behavioural and psychological symptoms of dementia (BPSD), such as depression. Caregivers and/or study partners will have the option of taking part in the study and providing feedback regarding the VR intervention. This project will explore how virtual reality can be used as a non-pharmacological approach to prolong aging in place for individuals with BPSD, as BPSD contributes to rates of institutionalization.
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.
Male or female participants aged 50 years of age
Has a history of previous clinical intracerebral hemorrhage.
Has probable CAA.
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).
Male or female participants aged 50 years of age to 90.
Must have a study partner
Participant- and/or Informant-reported history of cognitive decline with gradual onset and progression over the last 1 year before screening
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
Male or female participants aged 55 years of age to 90.
Must have a study partner
History of agitation due to AD.
The purpose of this study is to:Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) and Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration
Male or female participants aged 40 to 80 years of age
Has mild cognitive impairment (MCI) or dementia due to AD
Follow us: